Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

Documenti analoghi

• Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
  di: Yutaro Nagano, et al.
  Pubblicazione: (2026)
• Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
  di: Yuta Yamanaka, et al.
  Pubblicazione: (2024)
• Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
  di: Lisa Shigematsu, et al.
  Pubblicazione: (2025)
• Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
  di: Hiroshige Yoshioka, et al.
  Pubblicazione: (2025)
• Real‐World Outcomes of Induction Immunochemotherapy Followed by Surgery for Advanced Non‐Small Cell Lung Cancer
  di: Xingqi Mi, et al.
  Pubblicazione: (2026)